Is Becton, Dickinson & Co. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Becton, Dickinson & Co. has moved from very expensive to expensive. This suggests that the company is currently overvalued. Key valuation ratios include a P/E ratio of 33, an EV to EBITDA of 16.57, and a PEG ratio of 2.36, all indicating a premium valuation relative to its peers. For comparison, Abbott Laboratories has a P/E of 18.36 and Thermo Fisher Scientific, Inc. has an EV to EBITDA of 21.65, highlighting that Becton, Dickinson & Co. is trading at a higher valuation than these competitors.
In terms of recent performance, Becton, Dickinson & Co. has underperformed significantly against the S&P 500, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%. This further reinforces the notion that the stock may be overvalued in the current market environment.